PA8855001A1 - Monocarbamas - Google Patents

Monocarbamas

Info

Publication number
PA8855001A1
PA8855001A1 PA20098855001A PA8855001A PA8855001A1 PA 8855001 A1 PA8855001 A1 PA 8855001A1 PA 20098855001 A PA20098855001 A PA 20098855001A PA 8855001 A PA8855001 A PA 8855001A PA 8855001 A1 PA8855001 A1 PA 8855001A1
Authority
PA
Panama
Prior art keywords
monocarbamas
compounds
formula
refers
memory
Prior art date
Application number
PA20098855001A
Other languages
English (en)
Spanish (es)
Inventor
Singh Lall Manjinder
Edward Flanagan Mark
Joseph Brickner Steven
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8855001A1 publication Critical patent/PA8855001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
PA20098855001A 2008-12-19 2009-12-18 Monocarbamas PA8855001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13915908P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PA8855001A1 true PA8855001A1 (es) 2010-07-27

Family

ID=41727494

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098855001A PA8855001A1 (es) 2008-12-19 2009-12-18 Monocarbamas

Country Status (15)

Country Link
US (2) US8252782B2 (enExample)
EP (1) EP2379546A1 (enExample)
JP (1) JP2012512863A (enExample)
KR (1) KR20110086742A (enExample)
CN (1) CN102325769A (enExample)
AR (1) AR074801A1 (enExample)
AU (1) AU2009329169B2 (enExample)
CA (1) CA2744756C (enExample)
IL (1) IL213216A0 (enExample)
MX (1) MX2011006541A (enExample)
PA (1) PA8855001A1 (enExample)
SG (1) SG171781A1 (enExample)
TW (1) TW201026696A (enExample)
UY (1) UY32336A (enExample)
WO (1) WO2010070523A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379546A1 (en) * 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams
CA2815821C (en) * 2010-11-29 2015-07-07 Pfizer Inc. Monobactams useful for treating bacterial infections
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
HRP20201423T1 (hr) * 2015-09-23 2020-12-11 Novartis Ag Soli i čvrsti oblici antibiotika monobaktam
CN105481812B (zh) * 2015-11-30 2020-04-21 重庆天奕恒化科技有限公司 一种5-苄氧基-4-氧代-4h-吡喃-2-羧酸的制备方法
KR20190092566A (ko) 2016-12-21 2019-08-07 아이쿠리스 게엠베하 운트 코. 카게 항생제 내성 박테리아 균주에 의한 감염을 위한 아미딘 치환된 β-락탐 화합물 및 β-락타마제 억제제를 사용하는 조합 요법
AU2018311521B2 (en) 2017-08-02 2022-03-03 Novartis Ag Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
US11034648B2 (en) 2017-08-23 2021-06-15 Helmholtz-Zentrum Für Cystobactamide derivatives
AU2018325894B2 (en) 2017-08-31 2022-08-04 Hokko Chemical Industry Co., Ltd. 1-(N,N-disubstituted carbamoyl) 4-(substituted sulfonyl)triazolin-5-one derivatives, 4-(N,N-disubstituted carbamoyl) 1-(substituted sulfonyl)triazolin-5-one derivatives, and herbicide containing same as active ingredient
CN111511737B (zh) 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199981A (en) 1981-04-09 1985-08-16 Squibb & Sons Inc 2-oxo-1-(((substituted sulphonyl)amino)carbonyl)azetidines
US4587047A (en) * 1981-04-09 1986-05-06 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
JPH02502378A (ja) 1987-02-11 1990-08-02 ジ・アップジョン・カンパニー 抗生物質としての新規なＮ‐１置換β‐ラクタム
JPH02502455A (ja) * 1987-02-27 1990-08-09 ジ・アップジョン・カンパニー ピリドンカルボン酸または酸誘導体を含有する抗生物質β‐ラクタム
CA1317298C (en) * 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
US4762922A (en) * 1987-07-01 1988-08-09 Squibb Corporation 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US5015737A (en) * 1987-07-22 1991-05-14 The Upjohn Company Therapeutically useful beta-lactams
US4777252A (en) * 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
US4889930A (en) 1987-12-21 1989-12-26 E. R. Squibb & Sons, Inc. Process for making 2-oxo-1-((substituted sulfonyl)amino)carbonzyl)azetidines and intermediates used therein
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
EP0344707A3 (en) 1988-06-02 1990-04-18 E.R. Squibb & Sons, Inc. 2-Oxo-1-[[(substituted sulfonyl)-amino]carbonyl]-azetidine derivatives
US4959470A (en) * 1988-08-17 1990-09-25 E. R. Squibb & Sons, Inc. 2-oxo-[[(substituted sulfonyl)-amino]carbonyl]-azetidines
AU4064089A (en) 1988-09-27 1990-04-18 Upjohn Company, The Dihydroxyaryl 4-substituted monocarbams as antibiotics
CA2210787A1 (en) 1997-07-17 1999-01-17 William R. Collier Self-contained work station
MX2009009918A (es) 2007-03-23 2009-10-19 Basilea Pharmaceutica Ag Medicamentos combinados para el tratamiento de infecciones bacterianas.
EP2379546A1 (en) * 2008-12-19 2011-10-26 Pfizer Inc. Monocarbams

Also Published As

Publication number Publication date
UY32336A (es) 2010-07-30
US8252782B2 (en) 2012-08-28
MX2011006541A (es) 2011-07-20
TW201026696A (en) 2010-07-16
US8324198B1 (en) 2012-12-04
AU2009329169A1 (en) 2010-06-24
IL213216A0 (en) 2011-07-31
EP2379546A1 (en) 2011-10-26
AR074801A1 (es) 2011-02-16
AU2009329169B2 (en) 2012-06-28
CN102325769A (zh) 2012-01-18
CA2744756C (en) 2013-05-28
SG171781A1 (en) 2011-07-28
JP2012512863A (ja) 2012-06-07
WO2010070523A1 (en) 2010-06-24
US20120289455A1 (en) 2012-11-15
CA2744756A1 (en) 2010-06-24
KR20110086742A (ko) 2011-07-29
US20100160281A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
PA8855001A1 (es) Monocarbamas
CR11861A (es) Compuestos organicos
EA201170832A1 (ru) Пуриновые соединения
SV2011003855A (es) Heteroarilos sustituidos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
CY1118104T1 (el) Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
MY152114A (en) Novel pyrazole-4-n-alkoxycarboxamides as microbiocides
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
UY31524A1 (es) Nuevos compuestos 010
EA201170772A1 (ru) Органические соединения
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CO6361989A2 (es) Proceso para la preparacion de derivados de l-alanina protegidos
CR20140135A (es) Nuevos derivados de aril-quinolina
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UA106880C2 (uk) Нові гербіциди
CO6341625A2 (es) Derivados de indol como agentes anticáncer
TN2011000355A1 (en) Novel microbiocides
DOP2009000214A (es) Macrolidos basados en eritromicina
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.
CL2008003928A1 (es) Compuestos derivados de n-6-heterociclo-imidazo-[1,2-a]-piridin-2-carboxamida sustituidos; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.